THE CANCER RESEARCH TECHNOLOGY PIONEER FUND (CPF) today (Tuesday) has made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, to develop a promising class of drugs called MPS1 inhibitors to treat cancer.
23 April, 2013
As efforts to create a strong and effective vaccine for the dreaded dengue virus continue to hit snags, a new study from researchers at the La Jolla Institute for Allergy & Immunology offers surprising evidence that suggests the need for a revamped approach to dengue vaccine design. The finding runs counter to current scientific understanding of the key cells that need to be induced to develop a successful dengue vaccine.
16 April, 2013
Initiative strengthens drug development and commercialization network
15 April, 2013
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
05 April, 2013
Researchers at Roswell Park Cancer Institute (RPCI) have found that a new formulation of a promising anticancer agent, the small chemical molecule FL118, is even more effective in controlling two types of cancer than a version reported in PLOS ONE six months earlier proved to be. Additional evidence also suggests that the agent may successfully treat other solid tumors as well.
04 April, 2013
In the fight against malaria, cancer drugs are far from being considered a useful tool. But new research at Seattle BioMed reveals that liver cells, which are first infected by Plasmodium parasites after their transmission by mosquito bite, actually behave in similar ways to cancer cells. The work also shows that with the help of cancer drugs, the liver can become a hostile environment for the malaria parasite. This exciting new development is published in this month’s issue of the journal Cell Reports.
02 April, 2013